STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (ANAB) CFO option exercise and Rule 10b5-1 share sale detailed

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/16/2025, the CFO exercised an employee stock option to buy 10,000 shares of common stock at an exercise price of $20.16 per share, increasing directly held shares.

That same day, the CFO sold 9,365 shares at a weighted average price of $44.6152 per share and 6,360 shares at a weighted average price of $45.2062 per share under a pre-arranged Rule 10b5-1 trading plan adopted on April 11, 2025. After these transactions, the CFO directly owned 15,761 and then 9,401 shares of common stock and continued to hold 70,600 vested stock options reported in the table, plus additional options to purchase up to an aggregate of 339,440 shares that vest according to their terms.

Positive

  • None.

Negative

  • None.
Insider MULROY DENNIS
Role CHIEF FINANCIAL OFFICER
Sold 15,725 shs ($705K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 10,000 $0.00 --
Exercise Common Stock 10,000 $20.16 $202K
Sale Common Stock 9,365 $44.6152 $418K
Sale Common Stock 6,360 $45.2062 $288K
Holdings After Transaction: Employee Stock Option (right to buy) — 70,600 shares (Direct); Common Stock — 25,126 shares (Direct)
Footnotes (1)
  1. Reflects the acquisition of 1,324 shares acquired under the Company's ESPP. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested. In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MULROY DENNIS
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/16/2025 M 10,000 A $20.16 25,126(1) D
Common Stock 12/16/2025 S(2) 9,365 D $44.6152(3) 15,761 D
Common Stock 12/16/2025 S(2) 6,360 D $45.2062(4) 9,401 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $20.16 12/16/2025 M 10,000 (5) 07/12/2030 Common Stock 10,000 $0 70,600(6) D
Explanation of Responses:
1. Reflects the acquisition of 1,324 shares acquired under the Company's ESPP.
2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The stock option is fully vested.
6. In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.
/s/ Eric Loumeau, Attorney-in-Fact 12/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AnaptysBio (ANAB) disclose in this Form 4?

The filing reports that AnaptysBio's Chief Financial Officer exercised an employee stock option for 10,000 shares of common stock at an exercise price of $20.16 per share and sold shares on the same date.

How many AnaptysBio (ANAB) shares did the CFO sell and at what prices?

On 12/16/2025, the CFO sold 9,365 shares at a weighted average price of $44.6152 per share and 6,360 shares at a weighted average price of $45.2062 per share, with both figures reflecting multiple trades within disclosed price ranges.

Was the AnaptysBio CFO trade made under a Rule 10b5-1 plan?

Yes. The sale reported was effected pursuant to a Rule 10b5-1 trading plan that the CFO adopted on April 11, 2025, as noted in the explanation of responses.

How many AnaptysBio shares does the CFO own after the reported transactions?

Following the reported transactions on 12/16/2025, the CFO directly owned 9,401 shares of AnaptysBio common stock, as shown in Table I.

What stock options does the AnaptysBio CFO hold according to this filing?

Table II shows the CFO holds 70,600 derivative securities (stock options), including a fully vested option with an exercise price of $20.16 for 10,000 underlying shares. A footnote states the CFO also holds additional options to purchase up to an aggregate of 339,440 shares of common stock that vest according to their terms.

What is the role of the reporting person in AnaptysBio (ANAB)?

The reporting person is an officer of AnaptysBio, Inc., serving as the company's Chief Financial Officer, as indicated in the relationship section.